Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

emissions lasting in excess of two years in the great majority of patients treated."  

Study participants were enrolled selected to receive either ibrutinib 420 mg (n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were associated with overall response rates of 71 percent. Del17p patients had an overall response rate of 68 percent. Two patients in the 420 mg dose arm had complete responses and 34 patients had partial responses. Across all relapsed or refractory patients, including the high risk patients, the estimated progression-free survival at 26 months was 75 percent. An additional 20 percent of patients treated with the 420 mg dose and 15 percent of patients taking the 840 mg dose achieved a partial response accompanied by lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A total of six patients taking ibrutinib experienced an AE leading them to discontinue treatment with the drug. Severe AEs observed during the treatment period include pneumonia and dehydration (12 percent and six percent, respectively), as well anemia, neutropenia and thrombocytopenia (six percent, 15 percent and six percent, respectively). Grade 3-4 hematological toxicities were not common.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL. The primary objective of the study was to determine the safety of the two fixed-dose regimens of ibrutinib, assessed by evaluating the frequency and severity of AEs. Secondary efficacy endpoints included: overall response rate, progression-free survival and an exploratory endpoint of overa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... 1, 2014  Varian Medical Systems (NYSE: ... for the fourth quarter of fiscal year 2014 following ... 2014.  The news release will be followed by a ... PT.  The news release and a link to the ... website at: www.varian.com/investor .  To access the teleconference ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... 7 The 14th Annual Webby Awards named Regence BlueCross ... of Rich Media: Business to Consumer. More than a million people ... steep competition from companies that included Doritos® and NIKE. , ... The People,s Voice win ...
... May 7 Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: ... Officer, will be making a presentation at the MoneyShow Conference ... at Caesars Palace in Las Vegas .  Catalyst will ... and CPP-115. Further, the Company reported that its presentation materials ...
Cached Medicine Technology:Regence BlueCross BlueShield Wins People's Voice Award for Online Consumer Campaign in the 14th Annual Webby Awards 2Regence BlueCross BlueShield Wins People's Voice Award for Online Consumer Campaign in the 14th Annual Webby Awards 3Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Innovations announces ... scheduled to broadcast on Monday, October 20, 2014 at ... episode, Innovations will go behind the scenes to learn ... This segment will explore the practical help and information ... which teaches the warning signs of abuse, how to ...
(Date:10/1/2014)... Scientists at the University of Western Australia ... system proteins has the power to knock out mesothelioma ... the new study on their website. Click here ... the UWA School of Pathology and Laboratory Medicine administered ... mesothelioma with promising results. , “A timed triple ...
(Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
(Date:10/1/2014)... Two bicyclists began a journey on ... country in an effort to raise funds and awareness ... cyclists, a father-daughter team, plan to bike more than ... and finishing in Key West Florida. Funds raised ... a national nonprofit organization that assists post-9/11 service members, ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... Treatment Model Blends Eastern and Western Therapies to Create ... ... Feb. 13 Moonview Sanctuary, the exclusive,non-residential treatment and ... approaches practiced by more than 70,experts in their fields, ...
... SUINING, China, Feb. 13 /Xinhua-PRNewswire/ -- China Health ... that Jia Minru, famous,professor of the Chinese Medicine ... be responsible for deep development,high-tech development and systematic ... The joining of Jia Minru will certainly ...
... Calif., Feb. 12 Blue Cross of California,highly values ... members have with their physicians and medical groups. It ... and up to date,both for the benefit of our ... the ways we do this is to send the ...
... Event Name ... Same Commitment to ... the Health of all Babies, CINCINNATI, ... announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family will serve ... as WalkAmerica,March for Babies is the March of Dimes premier fundraising event ...
... (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and,diagnostics ... approximately,$2.3 million private financing with Montaur Capital through ... select institutional and strategic,investors of senior unsecured convertible ... principal amount of Senior Convertible,Notes to be issued ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
Cached Medicine News:Health News:High-End Treatment Center Moonview Sanctuary Unveils Four New Core Treatment Programs 2Health News:High-End Treatment Center Moonview Sanctuary Unveils Four New Core Treatment Programs 3Health News:Renowned Chinese Herbal Medicine Development Specialist Joins China Health Resources 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2